骨骼肌松弛剂治疗纤维肌痛:随机对照试验的系统综述与荟萃分析
该系统综述与荟萃分析纳入14项随机对照试验共1851例纤维肌痛患者,评估骨骼肌松弛剂对比安慰剂或活性镇痛药的疗效。结果显示骨骼肌松弛剂可小幅但显著降低疼痛评分(SMD=-0.24,95%CI=-0.32至-0.15,p<0.001),证据质量中等,但总体不良事件、疲劳、味觉异常及因不良事件停药的发生率增加。
要点
- 骨骼肌松弛剂对纤维肌痛疼痛有小幅显著改善,SMD=-0.24(95%CI -0.32至-0.15)。
- 抑郁、疲劳和睡眠质量也有小幅显著改善。
- 总体不良事件、疲劳、味觉异常及因不良事件停药增加。
核心结论
- 中等质量证据表明骨骼肌松弛剂与纤维肌痛患者疼痛强度小幅降低相关。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、EMBASE、Web of Science、ClinicalTrials.gov和Cochrane Library,纳入14项随机对照试验共1851例纤维肌痛患者。
主要发现
- 与安慰剂或活性治疗相比,骨骼肌松弛剂使疼痛评分小幅显著降低(SMD=-0.24,95%CI=-0.32至-0.15,p<0.001,95%预测区间=-0.40至-0.08)。
- 异质性无显著不一致(I2=0,95%CI=0%至50.79%),GRADE评级为中等。
- 次要结局显示抑郁、疲劳和睡眠质量有小幅但统计学显著的改善。
- 骨骼肌松弛剂与总体不良事件、疲劳、味觉异常及因不良事件停药的发生率增加相关。
临床怎么用
- 对于纤维肌痛患者,骨骼肌松弛剂可考虑作为疼痛管理的一种选择,但需权衡小幅获益与不良事件风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/IMPORTANCE: Fibromyalgia is a complex chronic pain disorder that significantly impairs patient well-being. Evaluating the efficacy of muscle relaxants for treating fibromyalgia is crucial for improving patient care. OBJECTIVE: This study aimed to evaluate the analgesic efficacy of muscle relaxants in patients with fibromyalgia. EVIDENCE REVIEW: A comprehensive literature search was conducted using PubMed, EMBASE, Web of Science, ClinicalTrials.gov, and the Cochrane Library. The search included randomized controlled trials (RCTs) comparing skeletal muscle relaxants with placebo/active analgesics for fibromyalgia. The primary outcome was pain intensity, measured by standardized mean difference (SMD) in pain scores. The risk of bias of included RCTs was assessed using the Cochrane Risk of Bias Assessment Instrument for Randomized Controlled Trials. FINDINGS: 14 RCTs (1851 participants) were included. Muscle relaxants were associated with a small but statistically significant reduction in pain scores compared with placebo or active treatment (SMD=-0.24, 95% CI=-0.32 to -0.15, p<0.001, 95% prediction interval=-0.40 to -0.08), with no significant inconsistency (I2=0, 95% CI=0% to 50.79%) and a moderate Grading of Recommendation, Assessment, Development and Evaluation rating. Secondary outcomes showed small, but statistically significant improvements in depression, fatigue and sleep quality. Muscle relaxants were associated with increased incidence of overall adverse effects, fatigue, abnormal taste, and drug withdrawal due to adverse effects. CONCLUSIONS: Moderate quality evidence showed that muscle relaxants were associated with a small reduction in pain intensity for patients with fibromyalgia.
引用
- Shing CH, Wang F, Lau LNL, et al. Skeletal muscle relaxant for the treatment of fibromyalgia: a systematic review and meta-analysis of randomized controlled trials. Reg Anesth Pain Med. 2025. PMID: 39532464. doi:10.1136/rapm-2024-105776
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。